Peptide ligands can be designed to function as molecular scaffolds specifically targeting IL13RA2 expressing GBM cells with molecular therapeutics while sparing normal brain tissue [6, 7, 12, 13]. This evidence concerns the gene IL13RA2 and glioblastoma.